vs
Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and Evolent Health, Inc. (EVH). Click either name above to swap in a different company.
Evolent Health, Inc. is the larger business by last-quarter revenue ($496.2M vs $267.3M, roughly 1.9× Ascendis Pharma A/S). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 2.6%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs -12.4%).
Ascendis Pharma A/SASNDEarnings & Financial Report
Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.
Magellan Health Inc., is an American for-profit managed health care company and subsidiary of Centene that focuses on special populations and other specialty areas of healthcare. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. It ranked 390 on the Fortune 500 in 2021.
ASND vs EVH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $267.3M | $496.2M |
| Net Profit | — | $-26.6M |
| Gross Margin | 90.5% | 16.9% |
| Operating Margin | — | — |
| Net Margin | — | -5.4% |
| Revenue YoY | 42.3% | 2.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $496.2M | ||
| Q4 25 | $267.3M | $468.7M | ||
| Q3 25 | $230.7M | $479.5M | ||
| Q2 25 | $170.7M | $444.3M | ||
| Q1 25 | $109.0M | $483.6M | ||
| Q4 24 | $187.8M | $646.5M | ||
| Q3 24 | $62.5M | $621.4M | ||
| Q2 24 | $38.9M | $647.1M |
| Q1 26 | — | $-26.6M | ||
| Q4 25 | — | $-429.1M | ||
| Q3 25 | $-65.9M | $-20.9M | ||
| Q2 25 | $-42.0M | $-19.9M | ||
| Q1 25 | $-102.2M | $-64.6M | ||
| Q4 24 | — | $-22.8M | ||
| Q3 24 | $-107.1M | $-23.1M | ||
| Q2 24 | $-118.1M | $1.6M |
| Q1 26 | — | 16.9% | ||
| Q4 25 | 90.5% | 20.7% | ||
| Q3 25 | 89.5% | 20.8% | ||
| Q2 25 | 80.1% | 22.6% | ||
| Q1 25 | 82.6% | 21.2% | ||
| Q4 24 | 91.9% | 11.7% | ||
| Q3 24 | 80.6% | 13.0% | ||
| Q2 24 | 68.2% | 16.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | -87.1% | ||
| Q3 25 | 5.1% | 0.2% | ||
| Q2 25 | -33.5% | -0.3% | ||
| Q1 25 | -103.2% | -0.3% | ||
| Q4 24 | — | -2.9% | ||
| Q3 24 | -167.3% | -2.6% | ||
| Q2 24 | -370.2% | 1.2% |
| Q1 26 | — | -5.4% | ||
| Q4 25 | — | -91.6% | ||
| Q3 25 | -28.5% | -4.4% | ||
| Q2 25 | -24.6% | -4.5% | ||
| Q1 25 | -93.7% | -13.4% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | -171.5% | -3.7% | ||
| Q2 24 | -303.9% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | $-3.76 | ||
| Q3 25 | — | $-0.24 | ||
| Q2 25 | — | $-0.44 | ||
| Q1 25 | — | $-0.63 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | — | $-0.27 | ||
| Q2 24 | — | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $665.3M | $142.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-175.8M | $396.4M |
| Total Assets | $1.4B | $1.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $142.0M | ||
| Q4 25 | $665.3M | $151.9M | ||
| Q3 25 | $582.2M | $116.7M | ||
| Q2 25 | $533.6M | $151.0M | ||
| Q1 25 | $559.4M | $246.5M | ||
| Q4 24 | $604.3M | $104.2M | ||
| Q3 24 | $675.6M | $96.6M | ||
| Q2 24 | $279.4M | $101.3M |
| Q1 26 | — | $396.4M | ||
| Q4 25 | $-175.8M | $415.2M | ||
| Q3 25 | $-188.0M | $842.2M | ||
| Q2 25 | $-202.6M | $896.0M | ||
| Q1 25 | $-205.0M | $935.5M | ||
| Q4 24 | $-114.2M | $1.0B | ||
| Q3 24 | $-105.1M | $1.0B | ||
| Q2 24 | $-346.8M | $1.1B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $1.4B | $1.9B | ||
| Q3 25 | $1.2B | $2.5B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.1B | $2.7B | ||
| Q4 24 | $1.3B | $2.5B | ||
| Q3 24 | $1.2B | $2.5B | ||
| Q2 24 | $819.0M | $2.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $58.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $58.2M | $48.8M | ||
| Q3 25 | — | $15.8M | ||
| Q2 25 | — | $-30.3M | ||
| Q1 25 | $-15.5M | $4.6M | ||
| Q4 24 | $-330.7M | $-26.2M | ||
| Q3 24 | — | $18.7M | ||
| Q2 24 | — | $21.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 13.42× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASND
Segment breakdown not available.
EVH
| Performance Suite | $323.3M | 65% |
| Specialty Technology and Services Suite | $80.8M | 16% |
| Administrative Services | $49.6M | 10% |
| Cases | $42.6M | 9% |
